AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
On May 25, 2017, Aimmune Therapeutics, Inc. (the Company) held
its Annual Meeting of Stockholders (the Annual Meeting). At the
Annual Meeting, the Companys stockholders voted on two proposals,
each of which is described in more detail in the Companys
definitive proxy statement on Schedule 14A filed with the
Securities and Exchange Commission on April 12, 2017. Only
stockholders of record as of the close of business on March 31,
2017, the record date for the Annual Meeting, were entitled to
vote at the Annual Meeting. As of the record date, 50,315,674
shares of the Companys common stock were outstanding and entitled
to vote at the Annual Meeting. The tabulation of the stockholder
votes on each proposal brought before the Annual Meeting is as
follows:
Proposal 1. The election of two directors to hold office until
the 2020 annual meeting of stockholders or until their respective
successor is elected:
|
Nominee |
Votes For |
Votes Withheld |
Broker Non-Votes |
|
Mark D. McDade |
33,396,557 |
3,343,810 |
10,776,300 |
|
Stacey D. Seltzer |
33,979,800 |
2,760,567 |
10,776,300 |
Proposal 2. The ratification of the selection, by the audit
committee of the board of directors of the Company, of KPMG, LLP,
as the independent registered public accounting firm of the
Company for the fiscal year ending December 31, 2017:
|
Votes For |
Votes Against |
Abstentions |
|
47,419,191 |
7,639 |
89,837 |
As a routine proposal under applicable rules, no broker non-votes
were recorded in connection with this proposal.
About AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT)
Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels. AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT) Recent Trading Information
AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT) closed its last trading session down -1.11 at 17.15 with 822,659 shares trading hands.
